The collaboration will combine Immatics’ Xpresident target discovery and T-cell receptor (TCR) capabilities with Amgen’s validated Bispecific T-cell Engager (BiTE) technology with the aim of creating novel oncology drugs.
List view / Grid view
Filter the results
26 August 2015 | By Victoria White
Immatics US is a new company aimed at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumour types...
25 August 2015 | By Victoria White
MorphoSys and Immatics have formed an alliance to generate antibody-based therapeutics against multiple proprietary cancer antigens recognised by T cells...